Master of Science, The Ohio State University, 2023, Human Ecology: Human Nutrition
Introduction. Alzheimer's disease (AD) is a progressive neurodegenerative and vascular disorder, representing the most common type of dementia. Beta-amyloid (A) plaques, tau tangles (T) and neurodegeneration (N), a combination known as the AT(N) feature, are pivotal changes in AD. Clinically, individuals with AD present with progressive cognitive impairment and memory loss. The preclinical phase, characterized by non-specific symptoms (i.e., anxiety and motor dysfunctions), occurs decades before the onset of debilitating symptoms; thus, representing a stage of the disease, when preventive measures may work best. Hypo- and hyperglycemia, related to hyperinsulinemia, are associated with neurodegeneration. Consequently, AD has recently been designated as “type 3 diabetes mellitus of the brain”. Oxidative stress, mitochondrial dysfunction, and both cerebral impaired glucose uptake and insulin resistance are examples of pathophysiological changes in early AD, which are reversible. Further research targeting the potential improvement of cerebral glucose homeostasis is required to reverse early AD abnormalities. Physiological insulin growth-factor binding protein 4 (IGFBP4, isolated from thermogenic cells) and the nanomaterial compound amino acid 2 (AAC2, capable of binding human insulin) are scaffolds with glycemic properties. In preliminary experimental models of diabetes, they were efficacious in delaying cognitive impairments and improving glucose metabolism. The potential role of these agents in AD has not been investigated so far.
Hypothesis. Human IGFBP4 (hIGFBP4) and AAC2, used as a single agent, or in combination will improve brain and body composition (fat, lean, and water content), behavior (learning, cognition, motor function, coordination, and anxiety-related symptoms), and metabolic profile (energy expenditure, activity, O2 and CO2 consumptions, and respiratory exchange rate) in an experimental AD murine model.
Material and Methods. 1-2-month-old APP/PS1 (open full item for complete abstract)
Committee: Ouliana Ziouzenkova, PhD (Advisor); Richard Bruno, PhD, RD (Committee Member); Tonya Orchard, PhD, MS, RD (Committee Member)
Subjects: Behavioral Sciences; Experiments; Medicine; Molecular Biology; Nanotechnology; Neurology; Neurosciences; Nutrition